Compare Diamondback Energy Inc (FANG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs BIO-TECHNE Corp — how do they compare? Diamondback Energy Inc trades at $201 (market cap $55.72B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Diamondback Energy Inc is far larger — about 5× BIO-TECHNE Corp's market cap, and Diamondback Energy Inc pays the higher dividend (2.21%). Which is the better fit depends on your goals.
| FANG | TECH | |
|---|---|---|
Market Cap | $55.72B | $11.24B |
Sector | Energy | Health |
52-Week High | $213.69 | $72.29 |
52-Week Low | $134.53 | $43.31 |
Enterprise Value | $67.87B | $11.32B |
Dividend Yield | 2.21% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $188.04, down 0.84% with bearish technical signals but strong fundamental performance. The company reported Q2 2026 earnings of $6.48 per share, beating estimates, with revenue growth driven by higher oil prices and production increases. Analyst consensus remains strongly bullish with a $236.63 price target, representing 26% upside potential from current levels.
FANG presents a compelling investment case with robust earnings momentum and strategic debt reduction, though elevated P/E ratio and commodity price volatility pose risks. The company's operational excellence and Permian Basin positioning support growth prospects, while technical indicators suggest near-term consolidation around support levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
